In addition, a small placebo-controlled and open study mentioned that rituximab achieved sustained clinical responses in patients with CFS [51], and a clinical trial demonstrated that rintatolimod, a restricted toll-like receptor 3 agonist, achieved significant improvements in patients with CFS [52]. This evidence concerns the gene TLR3 and myalgic encephalomeyelitis/chronic fatigue syndrome.